QCI Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

QCI Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-80	Closed	-$7K	–	649
2017 Q1	$7K	Buy	+80	New	+$7.12K	﹤0.01%	425
2016 Q4	–	Sell	-500	Closed	-$46K	–	527
2016 Q3	$46K	Hold	500	–	–	0.01%	208
2016 Q2	$39K	Hold	500	–	–	0.01%	232
2016 Q1	$41K	Hold	500	–	–	0.01%	222
2015 Q4	$52K	Hold	500	–	–	0.01%	190
2015 Q3	$53K	Hold	500	–	–	0.01%	194
2015 Q2	$68K	Hold	500	–	–	0.01%	164
2015 Q1	$62K	Buy	+500	New	+$53K	0.01%	168

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QCI Asset Management's BMRN Position: Q2 2017 in Review

QCI Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 80 shares — an estimated $7K sold.

QCI Asset Management first reported a position in BMRN in Q1 2015 and held it in 8 quarters. The position peaked at $68K in Q2 2015. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

QCI Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
QCI Asset Management sold 80 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $7K.
QCI Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 8 quarters.
QCI Asset Management's BioMarin Pharmaceuticals position peaked at $68K in Q2 2015.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on QCI Asset Management's 13F filing for Q2 2017, filed 8 Aug 2017.